Redburn Partners reiterated their sell rating on shares of BioNTech (NASDAQ:BNTX) in a report released on Wednesday, Analyst Ratings Network reports.
They currently have a $146.00 price target on the stock.
The analysts noted that the move was a valuation call.
A number of other brokerages also recently issued reports on BNTX. The Goldman Sachs Group assumed coverage on BioNTech in a research report on Tuesday, May 18th. They set a neutral rating and a $173.00 price target for the company. Berenberg Bank set a $130.00 target price on shares of BioNTech and gave the company a buy rating in a research report on Tuesday, April 6th. JPMorgan Chase & Co. set a $104.00 price target on shares of BioNTech and gave the stock a neutral rating in a report on Tuesday, April 6th. Zacks Investment Research upgraded shares of BioNTech from a hold rating to a strong-buy rating and set a $193.00 price objective on the stock in a research report on Friday, May 7th. Finally, Canaccord Genuity upped their target price on shares of BioNTech from $130.00 to $240.00 and gave the stock a buy rating in a research report on Wednesday, May 12th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $150.82.